Acute DiverticulitisNCT01825967
Acute Diverticulitis and C-Reactive Protein as a Prognostic Marker
An observational study of Acute Diverticulitis, run by Corporacion Parc Tauli at 4 sites in Spain.
Trial summary
The management of acute diverticulitis maybe better if we have prognostic markers of evolution. Hypothesis: C-reactive protein maybe a good prognostic marker of evolution of acute diverticulitis. The investigators need to know the values of C-reactive protein to predict evolution of acute diverticulitis. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Acute Diverticulitis
- What is being tested?
- C-reactive protein
- How many people
- 30 participants
- Where
- 4 sitesSpain
- Study dates
- Apr 2013to Apr 2014
- How long will I take part?
- 30 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All Patients with Acute Diverticulitis
Who may be able to join
- Acute Diverticulitis
Who cannot join
- Other Abdominal Pathologies
Trial locations and contacts
4 sites in 1 country.
Spain4 sites
Corporacion Parc Tauli
Sabadell, Barcelona, 08208
34937231010 ext. 21490, Lmora@tauli.cat
Laura Mora, 3493723101033 ext. 21490, Lmora@tauli.cat
Corporacion parc tauli
Sabadell, Sabadell-Barcelona, 08208
MORA L. LAURA, MD, 34639101033, Lmora@tauli.cat
MORA L. LAURA, MD
Corporacion Parc Tauli
Sabadell, Sabadell/barcelona, 08208
MORA L. LAURA, MD, 34639101033, Lmora@tauli.cat
Corporacion Parc Tauli
Sabadell, Sabadell/barcelona, 08208
About this study
Official title: Predictive Value of C-Reactive Protein in Acute Diverticulitis
The management of acute diverticulitis maybe better if we have prognostic markers of evolution.
Hypothesis: C-reactive protein maybe a good prognostic marker of evolution of acute diverticulitis.
The investigators need to know the values of C-reactive protein to predict evolution of acute diverticulitis.
Read the detailed description
A prospective observational study. All the patients with TC-diagnosis of acute diverticulitis (AD) had a C-reactive protein (PCR) in the initial blood test.
The investigators will predict evolution of AD with the PCR initial.
- Conditions
- Acute Diverticulitis
- Being tested
- C-reactive protein
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
C-reactive proteinOther
measured C-reactive protein in all patients with acute diverticulitis
| Study group | Role | What they receive |
|---|---|---|
| Acute Diverticulitis | We measured C-reactive protein in all the patients diagnosed with acute diverticulitis Receives: Other: C-reactive protein |
What is being measured
The primary outcome is the main question the study is designed to answer.
C-Reactive Protein
Measured: 24 Hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2013 (estimated)
- Study startApr 2013
- Primary completionApr 2014 (estimated)
- Study completionApr 2014 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute DiverticulitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
- Target duration
- 30 Days
Sponsor and investigators
- Lead sponsor
- Corporacion Parc Tauli
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, LAURA MORA LOPEZ, Corporacion Parc Tauli
- Investigators
- MORA LAURA, MD, Principal investigator, Corporacion Parc Tauli
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01825967
- Sponsor's protocol ID
- 2013/532
- Status last verified
- Apr 2013
- First submitted
- 29 Mar 2013
- Last updated
- 10 Apr 2013
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predictive Value of C-Reactive Protein in Acute Diverticulitis
- ClinicalTrials.gov ID
- NCT01825967
- Acronym / sponsor ID
- 2013/532
- Conditions
- Acute Diverticulitis
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Corporacion Parc TauliUniversity, hospital or other
- Study start
- Apr 2013
- Primary completion
- Apr 2014 (estimated)
- Study completion
- Apr 2014 (estimated)
- First posted
- 8 Apr 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The management of acute diverticulitis maybe better if we have prognostic markers of evolution.
Hypothesis: C-reactive protein maybe a good prognostic marker of evolution of acute diverticulitis.
The investigators need to know the values of C-reactive protein to predict evolution of acute diverticulitis.
Detailed description
A prospective observational study. All the patients with TC-diagnosis of acute diverticulitis (AD) had a C-reactive protein (PCR) in the initial blood test.
The investigators will predict evolution of AD with the PCR initial.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 30 Days
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Acute Diverticulitis | – | Other: C-reactive proteinWe measured C-reactive protein in all the patients diagnosed with acute diverticulitis |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All Patients with Acute Diverticulitis
Key inclusion criteria (1 listed)
- Acute Diverticulitis
Key exclusion criteria (1 listed)
- Other Abdominal Pathologies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| C-reactive proteinmeasured C-reactive protein in all patients with acute diverticulitis | Other | Acute Diverticulitis |
Primary outcome
C-Reactive Protein
Time frame: 24 Hours
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2013.
Related trials for Acute Diverticulitis
Not yet recruiting
Improving the Treatment of Acute Uncomplicated Diverticulitis in Routine Care
Diverticulitis
RecruitingPhase 2
APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)
Acute Uncomplicated Diverticulitis
Not yet recruitingObservational study
Analysis of the Role of the Microbiota in Diverticular Disease
Diverticular Disease of Colon, Acute Diverticulitis
Not yet recruitingObservational study
AIDE: Decision Support for Anastomosis or Colostomy in Emergency Surgery for Complicated Acute Diverticulitis
Complicated Diverticulitis, Acute Diverticulitis
RecruitingObservational study
Diagnosis of Abdominal Pain Using RNA Levels: The NATURAL Study
Intra Abdominal Infections, Appendicitis Acute
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
MORA LAURA, MD principal investigator
Corporacion Parc Tauli
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Diverticulitis, run by Corporacion Parc Tauli at 4 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Apr 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact MORA L. LAURA, MD (34639101033, Lmora@tauli.cat), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
C-Reactive Protein (time frame: 24 Hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2013.